Current state and progression of advanced melanoma treatment under precision medicine
DOI：10.3872/j.issn.1007-385x.2021.04.001
- VernacularTitle:精准医疗背景下晚期恶性黑色素瘤治疗的现状与进展
- Author:
ZHANG Jiaran
1
;
QI Zhonghui
1
;
SI Lu
1
Author Information
1. Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research [Ministry of Education], Peking University Cancer Hospital & Institute, Beijing 100142, China
- Publication Type:Journal Article
- Keywords:
advanced melanoma;
precision medicine;
tumor heterogeneity;
targeted therapy;
immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
2021;28(4):317-324
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] In the past, surgery and chemotherapy were the main treatment strategies for malignant melanoma, but companied with poor prognosis. With the development of high-throughput gene sequencing technology and the deepening understanding of tumor molecular mechanisms, it has been found that tumor heterogeneity and the diversity of tumor microenvironment affect tumor formation, drug resistance and treatment selection, leading to different responses and benefits of melanoma patients to the same treatment. The emerge and progression of targeted therapy and immunotherapy have significantly increased the survival rates of patients with metastatic melanoma, promoting the individualization and precision of melanoma treatment and making precise treatment a research hotspot as well as a trend. This review mainly summarizes the research progress of systemic individualized treatment of advanced melanoma based on precise subtyping and molecular level, and to get a more comprehensive view of the survival status of melanoma patients in the era of precision medicine, as well as the prospect and necessity of developing various targeted therapy, immunotherapy or combination therapy.
- Full text:20210401.pdf
